6CC0

Crystal structure of QscR bound to C12-homoserine lactone

  • Classification: TRANSCRIPTION
  • Organism(s): Pseudomonas aeruginosa
  • Expression System: Escherichia coli
  • Mutation(s): No 

  • Deposited: 2018-02-05 Released: 2018-02-28 
  • Deposition Author(s): Churchill, M.E.A., Wysoczynski-Horita, C.L.
  • Funding Organization(s): National Institutes of Health/National Institute of General Medical Sciences (NIH/NIGMS), National Institutes of Health/National Cancer Institute (NIH/NCI), National Institutes of Health/Office of the Director, National Institutes of Health/National Center for Advancing Translational Sciences (NIH/NCATS), National Science Foundation (NSF, United States)

Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.50 Å
  • R-Value Free: 0.270 
  • R-Value Work: 0.208 
  • R-Value Observed: 0.212 

wwPDB Validation   3D Report Full Report


Ligand Structure Quality Assessment 


This is version 1.4 of the entry. See complete history


Literature

Mechanism of agonism and antagonism of the Pseudomonas aeruginosa quorum sensing regulator QscR with non-native ligands.

Wysoczynski-Horita, C.L.Boursier, M.E.Hill, R.Hansen, K.Blackwell, H.E.Churchill, M.E.A.

(2018) Mol Microbiol 108: 240-257

  • DOI: https://doi.org/10.1111/mmi.13930
  • Primary Citation of Related Structures:  
    6CBQ, 6CC0

  • PubMed Abstract: 

    Pseudomonas aeruginosa is an opportunistic pathogen that uses the process of quorum sensing (QS) to coordinate the expression of many virulence genes. During quorum sensing, N-acyl-homoserine lactone (AHL) signaling molecules regulate the activity of three LuxR-type transcription factors, LasR, RhlR and QscR. To better understand P. aeruginosa QS signal reception, we examined the mechanism underlying the response of QscR to synthetic agonists and antagonists using biophysical and structural approaches. The structure of QscR bound to a synthetic agonist reveals a novel mode of ligand binding supporting a general mechanism for agonist activity. In turn, antagonists of QscR with partial agonist activity were found to destabilize and greatly impair QscR dimerization and DNA binding. These results highlight the diversity of LuxR-type receptor responses to small molecule agonists and antagonists and demonstrate the potential for chemical strategies for the selective targeting of individual QS systems.


  • Organizational Affiliation

    Department of Pharmacology and Program in Structural Biology and Biochemistry, University of Colorado School of Medicine, Aurora, CO 80045, USA.


Macromolecules
Find similar proteins by:  (by identity cutoff)  |  3D Structure
Entity ID: 1
MoleculeChains Sequence LengthOrganismDetailsImage
LuxR family transcriptional regulator
A, B
237Pseudomonas aeruginosaMutation(s): 0 
Gene Names: phzRqscRsdiA_2CAZ03_14830CAZ10_26210DC19_16645HQ52_16845PAERUG_E15_London_28_01_14_06284PAMH19_5306
UniProt
Find proteins for Q9RMS5 (Pseudomonas aeruginosa)
Explore Q9RMS5 
Go to UniProtKB:  Q9RMS5
Entity Groups  
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupQ9RMS5
Sequence Annotations
Expand
  • Reference Sequence
Small Molecules
Binding Affinity Annotations 
IDSourceBinding Affinity
EWM BindingDB:  6CC0 EC50: 5 (nM) from 1 assay(s)
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.50 Å
  • R-Value Free: 0.270 
  • R-Value Work: 0.208 
  • R-Value Observed: 0.212 
  • Space Group: P 21 21 21
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 57.591α = 90
b = 91.91β = 90
c = 93.999γ = 90
Software Package:
Software NamePurpose
PHENIXrefinement
XDSdata reduction
pointlessdata scaling
PHASERphasing

Structure Validation

View Full Validation Report



Ligand Structure Quality Assessment 


Entry History & Funding Information

Deposition Data


Funding OrganizationLocationGrant Number
National Institutes of Health/National Institute of General Medical Sciences (NIH/NIGMS)United StatesGM109403
National Institutes of Health/National Cancer Institute (NIH/NCI)United StatesP30CA046934
National Institutes of Health/Office of the DirectorUnited StatesS10OD012033
National Institutes of Health/National Center for Advancing Translational Sciences (NIH/NCATS)United StatesUL1TR001082
National Institutes of Health/Office of the DirectorUnited StatesS10OD12073
National Science Foundation (NSF, United States)United StatesDMR-1121288

Revision History  (Full details and data files)

  • Version 1.0: 2018-02-28
    Type: Initial release
  • Version 1.1: 2018-05-02
    Changes: Data collection, Database references
  • Version 1.2: 2019-11-27
    Changes: Author supporting evidence
  • Version 1.3: 2023-10-04
    Changes: Data collection, Database references, Refinement description
  • Version 1.4: 2024-03-13
    Changes: Source and taxonomy